Sandoz Breaks Off Digital Deal With Pear
Decision Follows Change In Sandoz Leadership
Executive Summary
Sandoz has announced that partner Pear Therapeutics will now market alone the reSET and reSET-O digital therapeutics launched by the pair in the US almost a year ago. The move follows Richard Saynor taking charge of Sandoz as part of the Novartis unit’s current transformation.
You may also be interested in...
Digital Health And Pharma Still Defining Rules Of Engagement
Despite all of the buzz around adoption of digital health tools and whopping VC investments in consumer-facing digital health firms, pharma has yet to articulate a business model for co-development or integration of behavior-modifying digital therapeutics into their portfolios.
How Novartis Is Tailoring Its Strategy In Asia Pacific, Middle East and Africa
Iris Zemzoum, Novartis Pharma's president for Asia Pacific, Middle East and Africa, outlines how the company is shaping its strategy in the region, which comes with “extremes” in market profiles, via a distinct archetype that factors in commonalities between national healthcare systems. The company is also progressing interesting initiatives in digital therapeutics.
BI Finds Right Fit For Digital Therapeutic Partnership With Click
Deal Snapshot: The firms are partnering on a digital therapeutic for schizophrenia in a deal potentially worth $500m.